The CNS dysfunction SWG will facilitate interdisciplinary collaborations focusing on approaches to better understanding CNS dysfunction among people with HIV. Our goals are: 1. Promote the growth of our diverse team through provision of resources and mentorship to young clinician and non-clinician investigators who have new interest in HIV research. We are particularly well-positioned to foster the success of those with interests in computational approaches to stratification and clinical prediction modeling, validation of biomarker targets for precision imaging, identification of new biomarkers (with informatics), and development of new precision techniques such as molecular-genetic imaging. ? Number of junior investigators involved with CNS dysfunction SWG ? Number of collaborations established within & across CFAR, including individuals new to HIV research or HIV-experienced & new to CNS dysfunction research ? Number of abstracts/manuscripts submitted by these junior or new investigators to CNS dysfunction HIV research ? Number of CFAR/P30 pilot or other awards to these junior or new investigators to CNS dysfunction HIV research 2. Facilitate the development and success of new protocols that generate new data (e.g., clinical, neuroimaging, biospecimens) or use existing clinical datasets such as the electronic health record (EHR), multi-domain neuropsychological and mental health data, biospecimen characteristics, and neuroimaging toward characterizing people with HIV with CNS dysfunction and comorbidities ? # of submitted NIH or other grants related to NeuroHIV ? # of submitted protocols that include novel expertise from outside the field of HIV/AIDS research ? # new manuscripts in NeuroHIV ? # CFAR scholar awards

Public Health Relevance

Despite effective antiretrovirals (ARVs), central nervous system (CNS) dysfunction persists in people with HIV (PWH). CNS dysfunction encompasses not only neurocognitive impairment (NCI) but also mental health disorders including major depressive and anxiety disorders. At present, we remain uncertain of the etiology of CNS dysfunction as well as the functional consequences. Consequently, we have been unsuccessful in developing interventions to improve neuropsychiatric signs and symptoms in HIV-infected individuals who are treated with ARVs. Toward improved care of those with HIV, the Office of AIDS Research has prioritized the study of CNS dysfunction and the numerous comorbidities which may have additive or synergistic effects on the CNS (e.g., vascular, metabolic, substance use) in PWH on ARVs who are virally suppressed. The CNS Dysfunction Scientific Working Group is a multidisciplinary team with interdisciplinary expertise in epidemiology, psychology, psychiatry, neurology, comparative and molecular biology, cognitive neuroscience, neuroimaging, immunology, bioinformatics, and mathematical modelling to better characterize people with HIV with CNS dysfunction and other comorbidities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI094189-08
Application #
9908391
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Wong, Elaine Wai-Ken
Project Start
Project End
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
8
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Bermudez, Laura Gauer; Ssewamala, Fred M; Neilands, Torsten B et al. (2018) Does Economic Strengthening Improve Viral Suppression Among Adolescents Living with HIV? Results From a Cluster Randomized Trial in Uganda. AIDS Behav 22:3763-3772
Sherman, Susan G; Hast, Marisa; Park, Ju Nyeong et al. (2018) Correlates of exchange sex among a population-based sample of low-income women who have heterosexual sex in Baltimore. AIDS Care 30:1273-1281
Lesko, Catherine R; Lau, Bryan; Chander, Geetanjali et al. (2018) Death after diagnosis of non-communicable disease comorbid conditions, stratified by injection drug use. AIDS :
Vincent, Kathleen Listiak; Moss, John A; Marzinke, Mark A et al. (2018) Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc. PLoS One 13:e0201952
Lee, Alice J; Montgomery, Madeline C; Patel, Rupa R et al. (2018) Improving Insurance and Health Care Systems to Ensure Better Access to Sexually Transmitted Disease Testing and Prevention. Sex Transm Dis 45:283-286
Pines, H A; Strathdee, S A; Hendrix, C W et al. (2018) Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border region. Int J STD AIDS :956462418793038
Van Pilsum Rasmussen, Sarah E; Bowring, Mary Grace; Shaffer, Ashton A et al. (2018) Knowledge, attitudes, and planned practice of HIV-positive to HIV-positive transplantation in US transplant centers. Clin Transplant 32:e13365
Lai, Shenghan; Heaphy, Christopher M; Rizzo, Anthony J et al. (2018) Cocaine use may induce telomere shortening in individuals with HIV infection. Prog Neuropsychopharmacol Biol Psychiatry 84:11-17
Shaffer, Ashton A; Thomas, Alvin G; Bowring, Mary Grace et al. (2018) Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey. Transpl Infect Dis 20:e12982
Seddon, J A; Weld, E D; Schaaf, H S et al. (2018) Conducting efficacy trials in children with MDR-TB: what is the rationale and how should they be done? Int J Tuberc Lung Dis 22:24-33

Showing the most recent 10 out of 724 publications